A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will
evaluate the efficacy and safety of giredestrant combined with palbociclib compared with
letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive,
human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or
progressed) or metastatic breast cancer.

Treatment Sites in Georgia